We hope this message finds you well. Prevent Blindness is helping VOZ Advisors, a consulting firm that specializes in patient advocacy and engagement during the drug development process. They are currently working with a global biopharmaceutical company to gain a deeper understanding of the challenges and experiences faced by individuals living with neovascular age-related macular degeneration [Read More]
News
Free Webinar: Therapeutic Targets for Dry AMD
David Boyer, M.D. – Therapeutic Targets for Dry AMD October 3, 2023 at 7:00 p.m. EDT Registration: https://bit.ly/45FfFdB The Foundation Fighting Blindness, the global leader in driving research for treatments and cures for blinding retinal diseases, will host a free webinar on Tuesday, October 3, 2023, from 7:00 – 8:00 p.m. ET. During the [Read More]
IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy
IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc. announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]
Prevent Blindness Accepting Applications For New ASPECT Program
The application period is now open for all who wish to participate in the ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program at Prevent Blindness. Individuals with vision impairment or blindness are welcome to participate, as well as allies (i.e. parents or guardians, care partners, nonprofit representatives, multidisciplinary clinicians, eye care providers, [Read More]
Loss of Confidence
A Message to the AMD Community from Dan Roberts 1998 I have experienced a symptom of vision loss, and I wonder if anyone else can relate to it. It is not physical, and it is not emotional. This is a much more subtle psychological symptom which seems to lurk in the background and affect nearly [Read More]